4.7 Article

Evaluation of the efficacy and the safety of lanreotide autogel 120 mg on tumor growth stabilization in patients with progressive neuroendocrine tumors (NETs) who are not eligible to surgery or chemotherapy.

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 29, Issue 15_suppl, Pages e14660-e14660

Publisher

American Society of Clinical Oncology (ASCO)
DOI: 10.1200/jco.2011.29.15_suppl.e14660

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available